Gut microbiome psychobiotics, extracellular vesicles therefrom, compositions comprising the same and methods of using same
Psychobiotic compositions derived from Bacteroides, Lactobacillus, and Bifidobacterium strains provide neuroactive compounds to treat psychiatric disorders and improve gut health by leveraging the gut-brain axis and immune modulation, addressing the lack of effective interventions in current therapies.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- UNIVERSITY OF OTTAWA
- Filing Date
- 2025-12-10
- Publication Date
- 2026-06-18
AI Technical Summary
Current therapies for psychiatric disorders, gut health, and inflammation lack effective interventions that leverage the gut microbiome's neuroactive compounds, particularly GABA and serotonin, to modulate brain function and immune responses.
Development of psychobiotic compositions comprising Bacteroides, Lactobacillus, and Bifidobacterium strains and their extracellular vesicles, which produce and deliver neuroactive compounds like GABA and 5-hydroxytryptophan, formulated as therapeutic, food, or feed additives to treat psychiatric disorders, improve gut health, and reduce inflammation.
The compositions effectively treat psychiatric disorders such as schizophrenia, autism, anxiety, and depression, improve gut health, and reduce both gut and systemic inflammation by utilizing the gut-brain axis signaling and immune modulation.
Smart Images

Figure 1 
Figure 2 
Figure 3